Document Detail

Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts.
MedLine Citation:
PMID:  21890304     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, exerts beneficial actions on cardiovascular complications. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts.
METHODS: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food admixture at a concentration of 0.01%, and the other did not (control). One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated deoxyuride-5'-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5' adenosine monophosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis.
RESULTS: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0.54 ± 0.04 mm(2)) vs control (0.93 ± 0.04 mm(2); n = 7; P < .01). Pioglitazone treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after implantation in the pioglitazone group (4.1% ± 1.1%) vs the controls (16.8% ± 1.7%; P < .05). The frequency of TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5% ± 0.5%) vs the controls (1.2% ± 0.1%; P < .05). Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein.
CONCLUSIONS: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.
Koichi Morisaki; Rei Shibata; Noriko Takahashi; Noriyuki Ouchi; Yoshihiko Maehara; Toyoaki Murohara; Kimihiro Komori
Related Documents :
17569984 - Morphologic evaluation of the caudal end of the inferior petrosal sinus using 3d rotati...
11110084 - Multiple dural arteriovenous fistulae involving the cavernous and sphenoparietal sinuses.
3204164 - Traumatic carotid-cavernous sinus fistula.
7966374 - Direct carotid-cavernous sinus fistulas.
20671254 - Small unruptured intracranial aneurysm verification study: suave study, japan.
25468094 - Bivalirudin and transcatheter aortic valve replacement: a cautionary tale.
Publication Detail:
Type:  Journal Article     Date:  2011-09-03
Journal Detail:
Title:  Journal of vascular surgery     Volume:  54     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-05     Completed Date:  2012-04-03     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1753-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
Division of Vascular Surgery, Department of Surgery, Nagoya University, Graduate School of Medicine, Nagoya, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carotid Artery, Common / pathology*,  surgery
Hyperplasia / etiology,  pathology,  prevention & control
Hypoglycemic Agents / therapeutic use*
Jugular Veins / transplantation*
Models, Animal
Thiazolidinediones / therapeutic use*
Tunica Intima / pathology*,  surgery
Vascular Grafting*
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Thiazolidinediones; 111025-46-8/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New method for absolute spinal cord ischemia protection in rabbits.
Next Document:  Novel use of endoluminal repair as prophylaxis of aortic rupture secondary to radiotherapy for lung ...